Description: Betahistine mesylate (also known as PT-9), the mono-HCl salt of Betahistine, is a potent histamine H3 receptor inhibitor with IC50 of 1.9 μM. Betahistine dihydrochloride is an anti-vertigo drug. It is commonly prescribed for balance disorders or to alleviate vertigo symptoms associated with Ménière's disease. It was first approved in Europe in 1970 for the treatment of Ménière's disease.

References: J Pharmacol Exp Ther. 2010 Sep 1;334(3):945-54; Eur Arch Otorhinolaryngol. 2003 Feb;260(2):73-7.

纯度：≥98%

CAS：54856-23-4